Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
Open Access
- 5 December 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (2) , 2848-2857
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Changcheng Zheng1, Xiaoyu Zhu1, Baolin Tang1, Xuhan Zhang1, Lei Zhang1, Liangquan Geng1, Huilan Liu1 and Zimin Sun1 1Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China Correspondence to: Zimin Sun, email: zmsun_vip@163.com Keywords: chronic myeloid leukemia; cord blood transplantation; chronic GVHD; GVHD/relapse-free survival; adolescent and young adult Received: March 22, 2017 Accepted: November 14, 2017 Published: December 05, 2017 ABSTRACT Adolescent and young adult (AYA) patients with hematological malignancy aged 15 to 39 years are recognized as a separate entity, and the efficacy and safety of unrelated cord blood transplantation (CBT) for chronic myeloid leukemia (CML) in AYA patients has not been reported. From March 2002 to June 2015, total of 106 CML patients received allogeneic hematopoietic cell transplantation (allo-HCT) in our center. Included in the present study were CML patients aged 15 to 39 years who received unrelated CBT or sibling allo-HCT, and 74 consecutive AYA patients with CML enrolled in this analysis. The day-100 cumulative incidences of grade 2–4 aGVHD and grade 3–4 aGVHD were similar following CBT and sibling-PBSCT/BMT. The cumulative incidences of cGVHD and extensive cGVHD were 21.7% and 5.3% in the CBT cohort, which were significantly lower than those in the sibling-PBSCT/BMT cohort (58.0% and 45.5%), respectively (p = 0.046, 0.008). There was no significant difference between the two cohorts in terms of transplant-related mortality (TRM), relapse, and long-term survival (overall survival and leukemia-free survival). The 5-year probability of GVHD-free/relapse-free survival (GRFS) was 47.9% and 33.4% in the CBT and the sibling-PBSCT/BMT cohorts, respectively (p = 0.632); among patients who survived more than 100 days after transplantation (n = 61), the 5-year probability of chronic GVHD-free, relapse-free survival (CRFS) was 66.2% in the CBT cohort, which was significantly higher than that in the sibling-PBSCT/BMT cohort (37.4%) (p = 0.037). Our study suggests that for AYA patients with CML, transplantation using unrelated CB offers comparable outcomes to sibling -PBSCT/BMT, including similar aGVHD, TRM, relapse, and long-term survival; however, from the perspective of quality of life, unrelated CBT have a lower incidence of cGVHD and a higher CRFS among survivors.Keywords
This publication has 26 references indexed in Scilit:
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisTransplantation and Cellular Therapy, 2016
- Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 2016
- Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road AheadCurrent Hematologic Malignancy Reports, 2015
- Comparison of Conditioning Regimens with or without Antithymocyte Globulin for Unrelated Cord Blood Transplantation in Children with High-Risk or Advanced Hematological MalignanciesTransplantation and Cellular Therapy, 2015
- Comparison of Unrelated Cord Blood Transplantation and HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia in Advanced StageTransplantation and Cellular Therapy, 2013
- A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donorsClinical Transplantation, 2013
- Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2013
- Diagnosis and management of chronic graft‐versus‐host diseaseBritish Journal of Haematology, 2012
- Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD ConsortiumBlood, 2011
- Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous LeukemiaTransplantation and Cellular Therapy, 2010